Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;9(1):84-6.
doi: 10.3816/CLM.2009.n.022.

Novel therapeutic agents in Waldenström's macroglobulinemia

Affiliations
Review

Novel therapeutic agents in Waldenström's macroglobulinemia

Irene M Ghobrial et al. Clin Lymphoma Myeloma. 2009 Mar.

Abstract

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

PubMed Disclaimer

References

    1. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679–685. - PubMed
    1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23:1564–1577. - PubMed
    1. Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:107–109. - PubMed
    1. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2006;107:3442–3446. - PubMed
    1. Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood. 2007;109:5096–5103. - PubMed

Publication types

MeSH terms